Cyclopentenylcytosine (CPE-C): In Vitro and In Vivo Evaluation as an Antiviral against Adenoviral Ocular Infections
Molecules · 2023
DOI: 10.3390/molecules28135078 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2023. Verfasst von Eric G Romanowski und 2 weiteren Autor:innen. Beteiligte Einrichtung: The Charles T. Campbell Ophthalmic Microbiology Laboratory, UPMC Vision Institute, Department of Ophthalmology, School of Medicine, University of Pit…. Hauptthemen laut MEDLINE: Organophosphonates, Adenoviruses, Human, Adenoviridae Infections, Eye Infections. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NEI NIH HHS, NIH, NIH Core Grant for Vision Research.
Abstract (Originalsprache)
Adenoviruses are the major cause of ocular viral infections worldwide. Currently, there is no approved antiviral treatment for these eye infections. Cyclopentenylcytosine (CPE-C) is an antiviral that has demonstrated activity against more than 20 viruses. The goals of the current study were to determine the in vitro and in vivo antiviral activity of CPE-C as well as its ocular toxicity. Antiviral activity was evaluated in vitro using standard plaque reduction assays to determine the 50% effective concentrations (EC50s) and in vivo in the Ad5/NZW rabbit ocular replication model. Ocular toxicity was determined in uninfected rabbit eyes following topical ocular application. The in vitro EC50s for CPE-C ranged from 0.03 to 0.059 μg/mL for nine adenovirus types that commonly infect the eye. Ocular toxicity testing determined CPE-C to be non-irritating or practically non-irritating by Draize scoring. In vivo, 3% CPE-C topically administered 4X or 2X daily for 7 days to adenovirus-infected eyes demonstrated effective antiviral activity compared with the negative control and comparable antiviral activity to the positive control, 0.5% cidofovir, topically administered twice daily for 7 days. We conclude CPE-C was relatively non-toxic to rabbit eyes and demonstrated potent anti-adenoviral activity in vitro and in vivo.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Charles T. Campbell Ophthalmic Microbiology Laboratory, UPMC Vision Institute, Department of Ophthalmology, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA.
ORCID-Profile: Eric G Romanowski, Kathleen A Yates
Förderung
- NEI NIH HHS
- NIH
- NIH Core Grant for Vision Research
- Eye & Ear Foundation of Pittsburgh
- University of Pittsburgh Department of Ophthalmology
Zitieren
APA
Romanowski, E. G., Yates, K. A., & Gordon, Y. J. (2023). Cyclopentenylcytosine (CPE-C): In Vitro and In Vivo Evaluation as an Antiviral against Adenoviral Ocular Infections. Molecules. https://doi.org/10.3390/molecules28135078
Vancouver
Romanowski EG, Yates KA, Gordon YJ. Cyclopentenylcytosine (CPE-C): In Vitro and In Vivo Evaluation as an Antiviral against Adenoviral Ocular Infections. Molecules. 2023. doi:10.3390/molecules28135078
BibTeX
@article{Romanowski2023,
author = {Romanowski, Eric G and Yates, Kathleen A and Gordon, Y Jerold},
title = {Cyclopentenylcytosine (CPE-C): In Vitro and In Vivo Evaluation as an Antiviral against Adenoviral Ocular Infections},
journal = {Molecules},
year = {2023},
doi = {10.3390/molecules28135078}
}
EUVIMED